- As per this agreement, AstraZeneca remains the holder of the registration for Pulmicort Respules and will manufacture the drug. Glenmark will commercialize the product in Colombia. -
/PRNewswire/ Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals.
/PRNewswire/ Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals.
ResearchAndMarkets.com’s offering.
“Asthma: Disease Insights and Market Forecasts to 2026” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Asthma disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Asthma, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.
Disease Indication Overview:
This section of the report gives the overview of Asthma disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Asthma disease. Further details on the profile of Asthma patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Asthma disease.